SELLAS Life Sciences Group, Inc.
SLS
$7.68
-$0.30-3.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 70.02% | -15.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.31% | 1.02% | |||
| Operating Income | -29.31% | -1.02% | |||
| Income Before Tax | -9.78% | -12.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.78% | -12.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.78% | -12.77% | |||
| EBIT | -29.31% | -1.02% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 10.15% | 13.42% | |||
| Normalized Basic EPS | -5.17% | 26.02% | |||
| EPS Diluted | 10.15% | 13.42% | |||
| Normalized Diluted EPS | -5.17% | 26.02% | |||
| Average Basic Shares Outstanding | 22.10% | 30.32% | |||
| Average Diluted Shares Outstanding | 22.10% | 30.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||